AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29762769
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for traumatic ASDH in younger patients
Trial: 29762769
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for traumatic ASDH in elderly patients (≥70 yr)
Trial: 29762769
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for traumatic ASDH in both younger and elderly patients
Trial: 29765616
Drug: Cumulative steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative steroid exposure (dose and duration) categorized into four levels: 0g (no exposure), >0 and <3.65g (<10mg/day for a year), ≥3.65g and <18.25g (1-5 years at 10mg/day), and ≥18.25g (>5 years at 10mg/day).
Trial: 29766026
Drug: Intrathecal AAV9
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal AAV9 Gene Therapy
Trial: 29766088
Drug: Community consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community consultation (CC) process using random digit dialing technique
Trial: 29766308
Drug: Laparoscopic TAPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic TAPP (l-TAPP)
Trial: 29766322
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily microcirculatory monitoring
Trial: 29766337
Drug: ASLAN-002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN-002 at 300 mg BID
Trial: 29766337
Drug: ASLAN-002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN-002 at 450 mg BID
Trial: 29766337
Drug: ASLAN-002 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN-002 (all doses)
Trial: 29766456
Drug: dNLR ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dNLR ≥ 1.35 in hormone receptor-negative/HER2+ population
Trial: 29766891
Drug: Intermittent heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent heparin infusion
Trial: 29766891
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on warfarin
Trial: 29767845
Drug: Defibrotide treatment
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide treatment after HSCT
Trial: 29767845
Drug: Defibrotide treatment
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide treatment in paediatric patients
Trial: 29767845
Drug: Defibrotide treatment
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide treatment in adult patients
Trial: 29767845
Drug: Defibrotide treatment
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide treatment without multi-organ dysfunction (MOD)
Trial: 29767845
Drug: Earlier initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Earlier initiation of defibrotide treatment after VOD/SOS diagnosis
Trial: 29768372
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention program including wearable devices, App for recording activities, counseling, physical activity program, and pelvic floor treatment.
Trial: 29769385
Drug: Panitumumab plus
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab plus Irinotecan (Pa 9 mg/m)
Trial: 29770748
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir (RAL) therapy for 8 weeks
Trial: 29773527
Drug: SMS triggered
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS triggered by missed or delayed doses
Trial: 29773698
Drug: Baseline CoMiSS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline CoMiSS score before AAF treatment.
Trial: 29774030
Drug: CSF-470 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSF-470 vaccine
Trial: 29774030
Drug: Medium-dose IFNα2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose IFNα2b
Trial: 29774169
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision.
Trial: 29775078
Drug: Developmental Reciprocity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmental Reciprocity Treatment
Trial: 29775807
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg on day 1 (21-day cycles)
Trial: 29776373
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg intravenously, weekly pegylated recombinant arginase (BCT-100)
Trial: 29777230
Drug: Baseline CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline CC levels
Trial: 29777230
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in CC levels
Trial: 29777402
Drug: Estrogen receptor/progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor/progesterone receptor-negative tumors
Trial: 29777865
Drug: Switching therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching therapy
Trial: 29778365
Drug: Cerebral microbleeds,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral microbleeds, diabetes, anticoagulant type, and HAS-BLED
Trial: 29778515
Drug: Fractional intradermal
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional intradermal vaccination with quadrivalent conjugate vaccine (MenACWY-CRM)
Trial: 29778515
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid conjugated vaccine (Nimenrix®)
Trial: 29778738
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide) with high-risk patients receiving additional vinblastine.
Trial: 29780414
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with trimethoprim-sulfamethoxazole
Trial: 29780852
Drug: ADS-5102 (amantadine)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADS-5102 (amantadine) extended release capsules, 274 mg once daily at bedtime for up to two years
Trial: 29781056
Drug: Lead-in cohort
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead-in cohort for carboplatin dose (arm 2a, n=6)
Trial: 29782642
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg twice daily (q12h) until month 3, then adjusted to either 5 or 10 mg q12h.
Trial: 29784469
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose (27,476 IU)
Trial: 29784469
Drug: Tapered doses
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered doses (10,447 IU, 3013 IU, 587 IU)
Trial: 29784469
Drug: Tapered doses
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered doses (158 IU, 31 IU)
Trial: 29784747
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with immunotherapies for cutaneous melanoma
Trial: 29784747
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment in metastatic melanoma
Trial: 29785473
Drug: Plasma melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma melatonin levels correlation with postoperative morphine consumption
Trial: 29785473
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in endogenous melatonin levels and morphine consumption
Trial: 29785539
Drug: Spironolactone 200
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 200 mg single dose
Trial: 29787575
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (IV tPA)
Trial: 29787734
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) including specific diaphragm techniques
Trial: 29788155
Drug: GDC-0575 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0575 and gemcitabine (1000 mg/m2 or 500 mg/m2)
Trial: 29788155
Drug: GDC-0575 monotherapy
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0575 monotherapy
Trial: 29788339
Drug: Cold chain
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold chain capacity of -60°C or colder for the STRIVE Ebola vaccine trial
Trial: 29788340
Drug: Utilizing nurses
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utilizing nurses to staff the clinical trial for the Ebola vaccine.
Trial: 29788349
Drug: Vaccine against
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine against Ebola
Trial: 29788343
Drug: Immediate vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate vaccination with rVSV∆G-ZEBOV-GP vaccine (within 7 days)
Trial: 29788345
Drug: rVSV∆G-ZEBOV-GP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rVSV∆G-ZEBOV-GP Vaccine
Trial: 29788348
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo or no vaccine)
Trial: 29788497
Drug: GSK2256098 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256098 (1000 mg, 750 mg, 500 mg; dosed twice daily)
Trial: 29788694
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months
Trial: 29789238
Drug: LD-TDV administered
RxNorm normalized name: Tdvax
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-TDV administered by PharmaJet
Trial: 29789238
Drug: Simultaneous injection
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous injection of two LD-TDV doses
Trial: 29789238
Drug: LD-TDV (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-TDV (one or two doses)
Trial: 29789238
Drug: LD-TDV (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-TDV (two doses given either concomitantly or 90 days apart)
Trial: 29789971
Drug: Restriction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restriction of intravenous fluid element
Trial: 29790103
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day)
Trial: 29790125
Drug: Therapeutic interventions
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic interventions for the management of bleeding (fluid replacement, red blood cells transfusion, prothrombin complex concentrates, antifibrinolytic drugs, idarucizumab)
Trial: 29792074
Drug: Tinnitus Retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Retraining Therapy (TRT) including tinnitus-specific educational counseling and sound therapy
Trial: 29792535
Drug: Veliparib (PARP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (PARP inhibitor) combined with topotecan
Trial: 29793587
Drug: Cefazolin 4
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin 4 g dose administered before surgery
Trial: 29794066
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day and octreotide 30 mg every 28 days
Trial: 29794089
Drug: Interventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional treatment and Craniotomy
Trial: 29794101
Drug: Systemic thrombolysis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic thrombolysis, endovascular treatment or both
Trial: 29796622
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplement intake >872 IU/d
Trial: 29796622
Drug: 25(OH)D concentration
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D concentration <13 ng/mL
Trial: 29796648
Drug: Essential Amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential Amino Acids (EAA) ingestion (6.8 g)
Trial: 30846089
Drug: Paclitaxel drug-coated
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel drug-coated balloon treatment
Trial: 29798831
Drug: Web-based transdiagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based transdiagnostic intervention (10 weeks, based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders)
Trial: 29799100
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide (1.5 mg supratherapeutic dose)
Trial: 29799545
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine 0.5 g/kg/day
Trial: 29800309
Drug: Live zoster
RxNorm normalized name: Varicella zoster vaccine (live/attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live zoster VZVOka vaccine
Trial: 29801465
Drug: Erlotinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib at 150 mg/day
Trial: 29801483
Drug: Mass-treatment with
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass-treatment with praziquantel tablets as part of a Department of Health Mass-Treatment Campaign for schistosomiasis.
Trial: 29801483
Drug: Focus Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focus Group Discussions and individual in-depth interviews to assess barriers to treatment.
Trial: 29801520
Drug: G + A intervention
RxNorm normalized name: penicillin G Prefilled Syringe [Bicillin L-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + A intervention (gambling intervention combined with problem drinking intervention)
Trial: 29801520
Drug: G-only intervention
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G-only intervention (targets only gambling issues)
Trial: 29802091
Drug: Trauma-informed cognitive
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-informed cognitive behavioral therapy (CBT), eight-session antenatal intervention.
Trial: 29802551
Drug: Amrubicin 40-80
RxNorm normalized name: valrubicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrubicin 40-80 mg/m² intravenously combined with lenalidomide and weekly dexamethasone
Trial: 29802636
Drug: Basal insulin-only
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin-only therapy
Trial: 29803987
Drug: Coronary artery
RxNorm normalized name: Drug-coated coronary artery stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary artery function-guided diagnosis and treatment
Trial: 29807287
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily for ≥5 days in combination with aspirin 100 mg
Trial: 29807396
Drug: ASP8273 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8273 300 mg once daily
Trial: 29807781
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) co-expressing dominant-negative TGF-βRII (dnTGF-βRII)
Trial: 29807781
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) without dnTGF-βRII (implied control)
Trial: 29807885
Drug: Gamified electronic
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamified electronic medication administration simulator
Trial: 29808308
Drug: Afatinib (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m2)
Trial: 29808308
Drug: Afatinib (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30, 40, or 50 mg) plus docetaxel
Trial: 29812996
Drug: Dasatinib plus
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib plus intensive chemotherapy
Trial: 29812996
Drug: Imatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib plus intensive chemotherapy (from COG AALL0031)
Trial: 29843792
Drug: Obinutuzumab 1000
RxNorm normalized name: obinutuzumab 1000 MG in 40 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab 1000 mg intravenously on days 1, 8, and 15 of cycle 1, and on day 1 of cycles 2-8 (24 weeks treatment period)
Trial: 29843792
Drug: Obinutuzumab 1000
RxNorm normalized name: obinutuzumab 1000 MG in 40 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab 1000 mg intravenously
Trial: 29846848
Drug: Nab-paclitaxel maintenance
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy
Trial: 29846848
Drug: Carboplatin +
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin + nab-paclitaxel combination therapy
Trial: 29848478
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous traditional Chinese medicine (TCM)
Trial: 29849651
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (SC-TCZ) 162 mg weekly
Trial: 29849841
Drug: Analgesics for
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics for cancer-related pain
Trial: 29849841
Drug: Physician assessment
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician assessment of analgesics
Trial: 29851546
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg daily until progressive disease/unacceptable toxicity
Trial: 29852037
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) at a dose of 54 Gy delivered in 3 fractions of 18 Gy over 1.5 to 2.0 weeks
Trial: 29852933
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) in combination with optimal medical therapy (OMT)
Trial: 29852973
Drug: Other glucose-lowering
RxNorm normalized name: Other blood glucose lowering drugs, excl. insulins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other glucose-lowering drugs (GLDs)
Trial: 29853437
Drug: Weekly newsletter
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly newsletter for 5 months (Control)
Trial: 29853657
Drug: Ziv-aflibercept and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept and ganetespib combination treatment